HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR mutant lung cancers that lack the second-site EGFR T790M mutation

EGFR-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs). The combination of EGFR-TKI afatinib and anti-EGFR antibody cetuximab can overcome acquired resistance in mouse models and human patients. Since afatinib is also a potent HER2 inhibitor, we...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Takezawa, Ken, Pirazzoli, Valentina, Arcila, Maria E., Nebhan, Caroline A., Song, Xiaoling, de Stanchina, Elisa, Ohashi, Kadoaki, Janjigian, Yelena Y., Spitzler, Paula J., Melnick, Mary Ann, Riely, Greg J., Kris, Mark G., Miller, Vincent A., Ladanyi, Marc, Politi, Katerina, Pao, William
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3473100/
https://ncbi.nlm.nih.gov/pubmed/22956644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0108
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados